Published in Cutis on June 01, 2007
Use of Oral Doxycycline for Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections. J Clin Aesthet Dermatol (2009) 0.81
Chronic administration of oral trimethoprim-sulfamethoxazole for acne vulgaris. J Clin Aesthet Dermatol (2011) 0.75
The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol (2006) 1.94
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol (2006) 1.79
Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol (2002) 1.50
Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol (2006) 1.43
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum (2003) 1.41
The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol (2011) 1.40
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Dermatofibrosarcoma protuberans: a case report and review of the literature. J Clin Aesthet Dermatol (2008) 1.16
Atypical mycobacterial cutaneous infections. Dermatol Clin (2009) 1.15
Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel). Inflammation (2002) 1.11
Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther (2006) 1.09
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol (2013) 1.08
Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol (2011) 1.07
Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis (2007) 1.03
Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol (2009) 0.98
Anti-inflammatory activity of tetracyclines. Dermatol Clin (2007) 0.98
Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthet Dermatol (2013) 0.98
Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation. Arthritis Rheum (2005) 0.98
Calciphylaxis: a review. J Clin Aesthet Dermatol (2008) 0.98
Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol (2009) 0.92
Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol (2010) 0.92
Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol (2009) 0.92
Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol (2012) 0.92
Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin (2009) 0.91
Acne Vulgaris and the Epidermal Barrier: Is Acne Vulgaris Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity of the Epidermal Barrier? J Clin Aesthet Dermatol (2013) 0.90
A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol (2009) 0.89
Psychosocial judgements and perceptions of adolescents with acne vulgaris: A blinded, controlled comparison of adult and peer evaluations. Biopsychosoc Med (2011) 0.87
Skin cancer in asians: part 2: melanoma. J Clin Aesthet Dermatol (2009) 0.87
Pathogenesis of acne vulgaris: what's new, what's interesting and what may be clinically relevant. J Drugs Dermatol (2011) 0.86
Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol (2008) 0.85
Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis (2009) 0.85
The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis (2007) 0.85
Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol (2011) 0.85
Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol (2008) 0.84
Solitary sclerotic fibroma. J Clin Aesthet Dermatol (2009) 0.84
Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol (2013) 0.84
Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol (2008) 0.83
Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol (2008) 0.83
Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol (2009) 0.81
Tretinoin photostability: comparison of micronized tretinoin (0.05%) gel and tretinoin (0.025%) gel following exposure to ultraviolet a light. J Clin Aesthet Dermatol (2012) 0.80
Absence of Degradation of Tretinoin When Benzoyl Peroxide is Combined with an Optimized Formulation of Tretinoin Gel (0.05%). J Clin Aesthet Dermatol (2010) 0.80
Combining clindamycin 1%-benzoyl peroxide 5% gel with multiple therapeutic options. Cutis (2006) 0.80
Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol (2013) 0.79
A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. Cutis (2009) 0.79
Tinea capitis in infants: recognition, evaluation, and management suggestions. J Clin Aesthet Dermatol (2012) 0.79
Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol (2011) 0.79
Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. J Clin Aesthet Dermatol (2009) 0.79
Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin (2007) 0.78
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia. Bioorg Med Chem Lett (2012) 0.78
Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol (2011) 0.78
Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin. J Clin Aesthet Dermatol (2011) 0.78
Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol (2016) 0.77
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. J Drugs Dermatol (2013) 0.77
Overcoming the Barrier Treatment of Ichthyosis: A Combination-therapy Approach. J Clin Aesthet Dermatol (2010) 0.77
Evolving perspectives on the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol (2015) 0.77
Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol (2012) 0.76
The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol (2013) 0.76
Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2014) 0.76
A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol (2010) 0.75
A Comprehensive Review of Clocortolone Pivalate 0.1% Cream: Structural Development, Formulation Characteristics, and Studies Supporting Treatment of Corticosteroid-responsive Dermatoses. J Clin Aesthet Dermatol (2012) 0.75
Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. J Clin Aesthet Dermatol (2010) 0.75
Avoiding the legal "blemish": medicolegal pitfalls in dermatology. J Clin Aesthet Dermatol (2009) 0.75
Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol (2009) 0.75
Efficacy and Tolerability of a Three-Step Acne System Containing a Solubilized Benzoyl Peroxide Lotion versus a Benzoyl Peroxide/Clindamycin Combination Product: An Investigator-Blind, Randomized, Parallel-Group Study. J Clin Aesthet Dermatol (2008) 0.75
Erythropoietic protoporphyria: a case report and literature review. J Clin Aesthet Dermatol (2010) 0.75
Primary carcinosarcoma of the ear: case report and review of the literature. J Clin Aesthet Dermatol (2009) 0.75
Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review. J Clin Aesthet Dermatol (2009) 0.75
Atopic dermatitis and the stratum corneum: part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin. J Clin Aesthet Dermatol (2013) 0.75
Message from the guest editor. J Drugs Dermatol (2012) 0.75
Acne and rosacea. J Drugs Dermatol (2008) 0.75
Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. J Drugs Dermatol (2013) 0.75
Overstating Conclusions from Population-Based Data: Be Careful What You Wish For! J Drugs Dermatol (2016) 0.75
Hyperkeratotic papular eruptions on legs, arms, and back. Int J Dermatol (2010) 0.75
Management of Acne & Rosacea: Working Toward the Same Goals…Facing New Challenges. J Drugs Dermatol (2015) 0.75
Laser and light-based therapies for acne vulgaris: a current guide based on available data. J Drugs Dermatol (2010) 0.75
Comparative efficacy and safety results of topical hemostatic powder and sterile compressed foam sponge in second intention healing following Mohs micrographic surgery. J Drugs Dermatol (2010) 0.75
Journal of Drugs in Dermatology: New methods and Techniques. Managing acne with adapalene 0.1% and 0.3% gels. Introduction. J Drugs Dermatol (2008) 0.75
The changing face of challenges in the management of acne and rosacea. J Drugs Dermatol (2014) 0.75
Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. J Drugs Dermatol (2014) 0.75
Why are dermatologists still talking about acne? Because so many people have it... and we are always seeking better ways to manage it. J Drugs Dermatol (2011) 0.75
Topical retinoids in the management of acne: the best path to clear results. Cutis (2004) 0.75
Topical tazarotene in acne vulgaris: treatment approaches. Cutis (2004) 0.75
The effect of benzoyl peroxide 9.8% emollient foam on reduction of Propionibacterium acnes on the back using a short contact therapy approach. J Drugs Dermatol (2012) 0.75
What more can we learn about acne and rosacea? Just keep reading, questioning, and searching for clinical relevance beyond the limitations of clinical trials. J Drugs Dermatol (2013) 0.75
The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2012) 0.75
Spotlight on the Use of Nitric Oxide in Dermatology: What Is It? What Does It Do? Can It Become an Important Addition to the Therapeutic Armamentarium for Skin Disease? J Drugs Dermatol (2017) 0.75
The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris. J Drugs Dermatol (2017) 0.75
We are making progress with both acne and rosacea--but, let's face it! We still have a long way to go. J Drugs Dermatol (2010) 0.75